Scarica l'app Stockscreener
1.54
6.10%
-0.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PACB Giù?
Forum
Previsione
Precedente Chiudi:
$1.64
Aprire:
$1.69
Volume 24 ore:
13.04M
Relative Volume:
1.19
Capitalizzazione di mercato:
$421.75M
Reddito:
$188.87M
Utile/perdita netta:
$-400.38M
Rapporto P/E:
-1.0267
EPS:
-1.5
Flusso di cassa netto:
$-260.90M
1 W Prestazione:
-16.76%
1M Prestazione:
-9.41%
6M Prestazione:
-0.32%
1 anno Prestazione:
-69.69%
Intervallo 1D:
$1.53
$1.69
Intervallo di 1 settimana:
$1.53
$2.01
Portata 52W:
$1.16
$6.09
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Nome
Pacific Biosciences Of California Inc
Settore
Industria
Telefono
650-521-8000
Indirizzo
1305 O'BRIEN DRIVE, MENLO PARK, CA
Confronta PACB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.54 | 421.75M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
134.92 | 234.01B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.49 | 154.20B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
382.78 | 146.06B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.94 | 115.42B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.30 | 43.23B | 5.72B | 4.17B | 490.10M | 6.97 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-11 | Downgrade | UBS | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-17 | Aggiornamento | UBS | Neutral → Buy |
| 2023-10-31 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-06-30 | Iniziato | Goldman | Buy |
| 2023-05-10 | Iniziato | Barclays | Equal Weight |
| 2023-03-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2023-01-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Neutral |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-09-27 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Iniziato | Cowen | Outperform |
| 2017-11-03 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Downgrade | CL King | Buy → Neutral |
| 2016-11-03 | Reiterato | Cantor Fitzgerald | Buy |
| 2016-06-27 | Iniziato | CL King | Buy |
| 2016-04-15 | Iniziato | First Analysis Sec | Overweight |
| 2016-02-04 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Reiterato | Cantor Fitzgerald | Buy |
| 2015-10-23 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-02-04 | Reiterato | Maxim Group | Buy |
| 2013-09-26 | Reiterato | Maxim Group | Buy |
| 2013-01-14 | Reiterato | Maxim Group | Buy |
Mostra tutto
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
Revenue Downgrade: Here's What Analysts Forecast For Pacific Biosciences of California, Inc. (NASDAQ:PACB) - Simply Wall St
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Analysts Just Slashed This Year's Revenue Estimates By 14% - Yahoo Finance
Analysts Issue Forecasts for PACB FY2025 Earnings - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Michele Farmer Sells 24,349 Shares - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
A chromosome-scale reference assembly of Vigna radiata enables delineation of centromeres and telomeres - Nature.com
How HiFi sequencing is making a difference for rare disease research at Children’s Mercy - Pacific Biosciences
Traders Purchase High Volume of Pacific Biosciences of California Call Options (NASDAQ:PACB) - MarketBeat
Pacific Biosciences Officer Sells Over 259K Shares - TradingView
PacBio to Present at TD Cowen's 45th Annual Health Care Conference on March 4, 2025 - Nasdaq
The Goldman Sachs Group Cuts Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.50 - MarketBeat
PacBio to Participate in TD Cowen's 45th Annual Health Care Conference - Quantisnow
Life sciences stocks fall on NIH funding concerns - MSN
Where Pacific Biosciences Stands With Analysts - Benzinga
Pacific Biosciences of California (NASDAQ:PACB) Stock Rating Upgraded by StockNews.com - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap DownTime to Sell? - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Announces Quarterly Earnings Results - MarketBeat
StockWatch: NIH Indirect Cost Cuts Shake Tools Stocks - Genetic Engineering & Biotechnology News
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now - MSN
Sumitomo Mitsui Trust Group Inc. Decreases Stock Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Stephens Reiterates Overweight Rating for Pacific Biosciences of California (NASDAQ:PACB) - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call Transcript - Insider Monkey
Pacific Biosciences of California Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Pacific Biosciences of California (PACB) to Release Quarterly Earnings on Thursday - MarketBeat
PacBio's Strategic Talent Move: 700K Share Package Signals Major Executive Addition - StockTitan
PacBio Grants Equity Incentive Award to New Employee - Quantisnow
PacBio Grants Equity Incentive Award to New Employee - GlobeNewswire Inc.
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Ca - GuruFocus.com
Pacific Biosciences of California (NASDAQ:PACB) Releases Earnings Results, Meets Estimates - MarketBeat
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday - Benzinga India
PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall - Yahoo Finance
UBS Adjusts Price Target on Pacific Biosciences of California to $1.50 From $2, Keeps Neutral Rating - Marketscreener.com
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Call Highlights: Navigating ... - Yahoo Finance
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Call Highlights: Navigating ... By GuruFocus - Investing.com Canada
Pacific Biosciences: Q4 Earnings Snapshot - Huron Daily Tribune
PacBio outlines 2025 revenue guidance of $155M-$170M amid new product launches - MSN
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates - MSN
Compared to Estimates, Pacific Biosciences (PACB) Q4 Earnings: A Look at Key Metrics - MSN
PacBio (NASDAQ:PACB) Misses Q4 Sales Targets - Yahoo Finance
Pacific Biosciences Of California, Inc. Q4 Earnings Summary - Nasdaq
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results - TradingView
PacBio Reports Q4 2024 Financial Results Highlighting Revenue Decline and Strategic Developments - Nasdaq
Pacific Biosciences of California, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
PacBio Earnings: $154M Debt Restructuring Win Masks 33% Revenue Decline - StockTitan
Pacific Biosciences Of California Q4 24 Earnings Conference Call At 4:30 PM ET - Nasdaq
Trump’s Cuts to Medical Research Are Hurting These Stocks - Barron's
How HiFi sequencing lays the groundwork for accelerating rare disease diagnostics in the clinic - Pacific Biosciences
PacBio (PACB) Q4 Earnings Report Preview: What To Look For By Stock Story - Investing.com Canada
PacBio (PACB) Q4 Earnings Report Preview: What To Look For - Yahoo Finance
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Report Preview: What To Expect - Yahoo Finance
Pacific Biosciences Of California Inc Azioni (PACB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pacific Biosciences Of California Inc Azioni (PACB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Van Oene Mark | See Remarks |
Feb 18 '25 |
Sale |
1.88 |
100,773 |
189,252 |
1,496,681 |
| HENRY CHRISTIAN O | See Remarks |
Feb 18 '25 |
Sale |
1.88 |
259,909 |
488,109 |
2,237,854 |
1.16%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):